MedTrace Logo

Factors Affecting Mortality in Covid-19 Disease

NCT06043115 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 619

Last updated 2023-09-21

No results posted yet for this study

Summary

The coronavirus disease-19 (COVID-19), defined by the reporting of pneumonia cases of unknown etiology at the end of 2019 in Wuhan, China, has spread worldwide, causing millions of deaths. Despite the fact that more than two years have passed since the struggle against the disease it continues to be an important public health problem.The increasing number of critically ill patients with this pandemic caused a great demand for intensive care units (ICU), and ICU capacity and staff had to be rapidly expanded in many countries. Similarly, in various periods of the pandemic in Turkey, the capacity of many ICUs had to be increased. The rates of admission to the ICU and death rates differed greatly from center to center due to various factors such as ICU bed capacity and the duration of access to the ICU, patient characteristics, and differences in the treatments applied. Determining the factors that may be associated with mortality is important in terms of improving the ICU follow-up of patients with COVID-19 and guiding their treatment.There is limited information about the characteristics and mortality of Turkish patients with COVID-19 in the ICU. The aim of this study is to determine the demographic, clinical and laboratory characteristics and the factors affecting ICU mortality in COVID-19 patients followed in Akdeniz University Medical Faculty Hospital since the beginning of the pandemic.

Conditions

Interventions

OTHER

covid-19 survival cohort

consists of surviving patients

OTHER

covid-19 mortality cohort

consists of deceased patients

Sponsors & Collaborators

  • Melike Cengiz

    lead OTHER

Principal Investigators

  • Burcu Ozer, MD · Akdeniz University School of Medicine, Department of Anesthesiology and Reanimation, Turkey

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-11
Primary Completion
2022-11-30
Completion
2022-12-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06043115 on ClinicalTrials.gov